Lack of association between methylenetetrahydrofolate dehydrogenase 1 G1958A polymorphism and prostate cancer risk: a meta-analysis

• Published in: Tumor biology 2014-03, Vol.35 (3), p.2029-2033
• Main Authors: Liu, Guizhong, Qi, Can, Xu, Qingzhu, Wu, Baojun, Wang, Yingjie, Xue, Chunxiao
• Format: Article
• Language: English
• Subjects: Biomedical and Life Sciences; Biomedicine; Cancer Research; Case-Control Studies; Genetic Predisposition to Disease - genetics; Genetics; Humans; Male; Meta-analysis; Methylenetetrahydrofolate Dehydrogenase (NADP) - genetics; Minor Histocompatibility Antigens; Odds Ratio; Polymorphism; Polymorphism, Single Nucleotide - genetics; Prostate cancer; Prostatic Neoplasms - genetics; Research Article; Risk assessment; Risk Factors
• ISSN: 1010-4283; 1423-0380
• DOI: 10.1007/s13277-013-1269-y

The methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) polymorphism G1958A has been extensively investigated as a potential risk factor for prostate cancer (PCa), but the results have thus far been inconclusive. This meta-analysis was performed to derive a more precise estimation of the association. A comprehensive search was conducted to identify all case–control studies of MTHFD1 G1958A polymorphism and PCa risk. We used odds ratios (ORs) to assess the strength of the association, and 95 % confidence intervals (CIs) give a sense of the precision of the estimate. Statistical analyses were performed using Review Manage version 5.0 and Stata 10.0. A total of six available studies were considered in the present meta-analysis, with 7,493 patients and 36,941 controls. When all groups were pooled, there was no evidence that G1958A had significant association with PCa under additive, recessive, dominant, and allelic models. This meta-analysis suggests that MTHFD1 G1958A polymorphism might not be a risk factor for PCa. However, further large-scale and well-designed case–control studies are necessary to validate the risk identified in the present meta-analysis.